CARD9 and type 1 diabetes mellitus: These findings define a novel sympathetic‐macrophage‐creatine metabolic axis governed by CARD9 that links neural signals to immune and metabolic regulation in T1D, highlighting neuroimmune interactions as targets for therapies.